文献速递睡眠呼吸障碍

胰高血糖素样肽-1受体激动剂治疗阻塞性睡眠呼吸暂停综述

Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-01-01

该综述指出,GLP-1受体激动剂可降低肥胖OSA患者的AHI,替尔泊肽已获FDA批准用于中重度OSA,但疗效不及CPAP,心血管获益未证实,停药后体重易反弹。

要点

  • GLP-1 RAs可降低AHI,替尔泊肽使42%-50%患者达到疾病缓解。
  • GLP-1 RAs应作为CPAP的辅助治疗,或用于术前优化及扩大舌下神经刺激器适应人群。
  • 适用于BMI>30且CPAP不耐受或有肥胖相关共病的患者,不适用于无肥胖或主要为解剖性阻塞者。

核心结论

  • GLP-1 RAs为肥胖相关OSA提供疾病修饰性辅助治疗,宜与CPAP联合、用于术前优化或可能扩大舌下神经刺激器适应人群。

研究设计与样本

  • 综述纳入6项荟萃分析及SURMOUNT-OSA III期试验等证据。

主要发现

  • 6项荟萃分析显示GLP-1 RAs一致降低AHI,范围为-5.7至-21.9次/小时。
  • SURMOUNT-OSA III期试验显示替尔泊肽较安慰剂降低AHI 20至24次/小时,42%至50%患者达到疾病缓解(AHI<5次/小时或<15次/小时且无症状)。
  • GLP-1 RAs疗效不及CPAP(AHI降低约22 vs 31次/小时),心血管结局获益未证实,停药后体重常反弹。

关键数值与推荐

  • 推荐用于BMI>30且CPAP不耐受或有肥胖相关共病的患者。
  • 不推荐用于无肥胖或主要为解剖性阻塞的个体。

临床怎么用

  • 耳鼻咽喉科可将GLP-1 RAs作为CPAP的辅助治疗、上气道手术前优化或潜在扩大舌下神经刺激器适应人群。
  • 适用人群为BMI>30且CPAP不耐受或有肥胖相关共病者,不适用于无肥胖或解剖性阻塞为主者。

局限性

  • 与咽部临界闭合压、药物诱导睡眠内镜塌陷模式及舌下神经刺激器联合治疗结局相关的证据缺口关键。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Obstructive sleep apnea (OSA) affects nearly 1 billion adults worldwide and is independently associated with cardiovascular disease, stroke, and increased mortality. While continuous positive airway pressure (CPAP) remains the criterion standard treatment, adherence rates of only 30% to 60% limit its population-level effectiveness. Obesity is present in 60% to 70% of patients with OSA and represents the primary modifiable risk factor, yet, until recently, no pharmacological therapies specifically targeted this pathophysiological mechanism. The December 2024 US Food and Drug Administration approval of tirzepatide as the first medication indicated for moderate to severe OSA in adults with obesity represents a paradigm shift toward disease-modifying pharmacotherapy, with implications for otolaryngologic practice. OBSERVATIONS: Six meta-analyses demonstrated consistent apnea-hypopnea index (AHI) reductions with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), ranging from -5.7 to -21.9 events per hour. The SURMOUNT-OSA phase 3 trials showed that tirzepatide reduced AHI by 20 to 24 events per hour vs placebo, with 42% to 50% of patients experiencing disease remission (AHI, <5 events per hour or <15 without symptoms). Weight loss is the primary established mechanism, with GLP-1 RAs reducing tongue fat and parapharyngeal adipose tissue that contribute to upper airway collapse. Emerging preclinical evidence has suggested potential weight-independent effects through carotid body glucagon-like peptide 1 receptor modulation of chemosensitivity (affecting loop gain), leptin pathway interactions that are associated with upper airway neuromuscular control, and NLRP3 inflammasome suppression. However, GLP-1 RAs did not match CPAP efficacy (approximately22 vs 31 events per hour of an AHI reduction), cardiovascular outcome benefits remain unproven, and weight regain commonly occurs after discontinuation. CONCLUSIONS AND RELEVANCE: This review suggest that GLP-1 RAs offer otolaryngologists a disease-modifying adjunct for obesity-related OSA that is best positioned as complementary therapy alongside CPAP, preoperative optimization before upper airway surgery, or potentially to expand hypoglossal nerve stimulator candidacy. They are appropriate for patients with a body mass index (calculated as weight in kilograms divided by height in meters squared) greater than 30 who are CPAP-intolerant or have obesity-related comorbidities but are unlikely to benefit individuals without obesity or those with primarily anatomical obstruction. Critical evidence gaps include associations with pharyngeal critical closing pressure, drug-induced sleep endoscopy collapse patterns, and hypoglossal nerve stimulator combination therapy outcomes.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Harris A, Kaffenberger T. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42690639. doi:10.1001/jamaoto.2026.2266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。